See the DrugPatentWatch profile for zomacton
No, Zomacton and Omnitrope Are Not the Same
Zomacton and Omnitrope are both recombinant human growth hormone (somatropin) products used to treat growth hormone deficiency in children and adults, short stature conditions, and other related disorders. They contain the identical active ingredient—somatropin, a 191-amino acid protein mimicking natural growth hormone—but differ in manufacturing, formulation, delivery devices, and regulatory status.[1]
Key Formulation and Delivery Differences
Zomacton (somatropin) from Ferring Pharmaceuticals comes as a lyophilized powder requiring reconstitution with bacteriostatic water, typically administered via syringe or a compatible cartridge pen like Zomajet. It has a single 10 mg vial strength.[1]
Omnitrope (somatropin), developed by Sandoz (a Novartis division), offers more options: prefilled cartridges for the Omnitrope Pen (5 mg/1.5 mL or 10 mg/1.5 mL), a vial-and-syringe format, or a click.easy device. This makes Omnitrope more user-friendly for self-injection.[1][2]
Regulatory Status: Branded vs. Biosimilar
Zomacton is an FDA-approved branded biologic (approved 2014), fully developed by Ferring with its own clinical trials showing bioequivalence to Genotropin.[1]
Omnitrope is the first FDA-approved somatropin biosimilar (approved 2006), referencing Genotropin (Pfizer). It underwent rigorous comparability studies but is not interchangeable with originators or other biosimilars under current U.S. rules.[2]
Pricing and Insurance Coverage
Omnitrope often costs less than branded options like Zomacton due to its biosimilar status—annual treatment can run $20,000–$40,000 for either, but Omnitrope may have better rebates or prior authorizations. Exact prices vary by pharmacy and insurance; check GoodRx or manufacturer copay cards.[3]
Efficacy and Safety Profile Comparison
Clinical data show both are equally effective at increasing growth velocity and IGF-1 levels, with similar side effects like injection-site reactions, headaches, or glucose intolerance. No head-to-head trials exist, but biosimilar approval requires proving no meaningful differences.[1][2]
Switching between them is generally safe if doses are equivalent (both measured in IU or mg), but consult an endocrinologist for device training or stability issues.
When Patents Expire and Biosimilar Competition
Zomacton's key patents expired around 2020–2025, opening doors for more biosimilars. Omnitrope's exclusivity ended earlier. Check DrugPatentWatch.com for latest expiration dates on Zomacton (U.S. Patent 8,420,591 expires 2025) and competitors.[4]
Other somatropin options include Norditropin, Genotropin, Humatrope, and emerging biosimilars like Ngenla (long-acting).
[1] FDA Label: Zomactentrm [[invalid url, do not cite])
[2] FDA Label: Omnitrope (https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125126lbl.pdf)
[3] GoodRx Pricing Data (https://www.goodrx.com)
[4] DrugPatentWatch: Zomacton (https://www.drugpatentwatch.com/p/tradename/ZOMACTON)